Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.
Facchinetti F, Hollebecque A, Braye F, Vasseur D, Pradat Y, Bahleda R, Pobel C, Bigot L, Déas O, Florez Arango JD, Guaitoli G, Mizuta H, Combarel D, Tselikas L, Michiels S, Nikolaev SI, Scoazec JY, Ponce-Aix S, Besse B, Olaussen KA, Loriot Y, Friboulet L. Facchinetti F, et al. Among authors: vasseur d. Cancer Discov. 2023 Sep 6;13(9):1998-2011. doi: 10.1158/2159-8290.CD-22-1441. Cancer Discov. 2023. PMID: 37377403 Free PMC article.
Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer.
Geraud A, Mezquita L, Auclin E, Combarel D, Delahousse J, Gougis P, Massard C, Jovelet C, Caramella C, Adam J, Naltet C, Lavaud P, Gazzah A, Lacroix L, Rouleau E, Vasseur D, Mir O, Planchard D, Paci A, Besse B. Geraud A, et al. Among authors: vasseur d. Cancers (Basel). 2020 Dec 14;12(12):3758. doi: 10.3390/cancers12123758. Cancers (Basel). 2020. PMID: 33327482 Free PMC article.
Detection of additional occult malignancy through profiling of ctDNA in late-stage cancer patients.
Aldea M, Cerbone L, Bayle A, Parisi C, Sarkozy C, Vasseur D, Verlingue L, Blanc-Durand F, Mosele F, Sakkal M, Ponce S, Lavaud P, Loriot Y, Hollebecque A, Massard C, Soria JC, Lacroix L, Rouleau E, Italiano A. Aldea M, et al. Among authors: vasseur d. Ann Oncol. 2021 Dec;32(12):1642-1645. doi: 10.1016/j.annonc.2021.09.002. Epub 2021 Sep 9. Ann Oncol. 2021. PMID: 34509616 Free article. No abstract available.
Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients.
Chen J, Facchinetti F, Braye F, Yurchenko AA, Bigot L, Ponce S, Planchard D, Gazzah A, Nikolaev S, Michiels S, Vasseur D, Lacroix L, Tselikas L, Nobre C, Olaussen KA, Andre F, Scoazec JY, Barlesi F, Soria JC, Loriot Y, Besse B, Friboulet L. Chen J, et al. Among authors: vasseur d. Ann Oncol. 2022 Apr;33(4):434-444. doi: 10.1016/j.annonc.2022.01.004. Epub 2022 Jan 21. Ann Oncol. 2022. PMID: 35066105 Free article. Clinical Trial.
Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer.
Riudavets M, Lamberts V, Vasseur D, Auclin E, Aldea M, Jovelet C, Naltet C, Lavaud P, Gazzah A, Aboubakar F, Dorta M, Remon J, Rouleau E, Ngocamus M, Nicotra C, Lacroix L, Besse B, Mezquita L, Planchard D. Riudavets M, et al. Among authors: vasseur d. Clin Lung Cancer. 2022 Sep;23(6):e377-e383. doi: 10.1016/j.cllc.2022.05.010. Epub 2022 May 11. Clin Lung Cancer. 2022. PMID: 35660356
Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test.
Vasseur D, Sassi H, Bayle A, Tagliamento M, Besse B, Marzac C, Arbab A, Auger N, Cotteret S, Aldea M, Blanc-Durand F, Géraud A, Gazzah A, Loriot Y, Hollebecque A, Martín-Romano P, Ngo-Camus M, Nicotra C, Ponce S, Sakkal M, Caron O, Smolenschi C, Micol JB, Italiano A, Rouleau E, Lacroix L. Vasseur D, et al. Cells. 2022 Jun 11;11(12):1901. doi: 10.3390/cells11121901. Cells. 2022. PMID: 35741030 Free PMC article. Review.
Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM).
Bayle A, Peyraud F, Belcaid L, Brunet M, Aldea M, Clodion R, Dubos P, Vasseur D, Nicotra C, Geraud A, Sakkal M, Cerbone L, Blanc-Durand F, Mosele F, Martin Romano P, Ngo Camus M, Soubeyran I, Khalifa E, Alame M, Blouin L, Dinart D, Bellera C, Hollebecque A, Ponce S, Loriot Y, Besse B, Lacroix L, Rouleau E, Barlesi F, Andre F, Italiano A. Bayle A, et al. Among authors: vasseur d. Ann Oncol. 2022 Dec;33(12):1328-1331. doi: 10.1016/j.annonc.2022.08.089. Epub 2022 Sep 17. Ann Oncol. 2022. PMID: 36122799 Free article. No abstract available.
65 results